Seth Zuckerman

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Efficacy of conventional opioids can be limited by adverse events (AEs). TRV130 is a structurally novel biased ligand of the μ-opioid receptor that activates G protein signaling with little β-arrestin recruitment. In this phase 2, randomized, placebo- and active-controlled study, we investigated the efficacy and tolerability of TRV130 in acute pain after(More)
  • 1